Tarsus Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	1,194	670	391	465	840
Market Cap Growth	-	71.44%	-15.95%	-44.60%	-
Enterprise Value	997	473	193	293	672
PE Ratio	-4.93	-4.93	-6.30	-33.65	-31.32
PS Ratio	68.46	38.42	15.15	8.16	-
PB Ratio	6.06	3.40	2.03	2.79	5.06
P/FCF Ratio	-5.45	-5.45	-7.89	147.13	-38.89
P/OCF Ratio	-5.71	-5.71	-7.98	124.13	-39.73
EV/Sales Ratio	57.13	27.10	7.49	5.15	-
EV/EBITDA Ratio	-3.61	-3.61	-3.27	-22.29	-25.29
EV/EBIT Ratio	-3.57	-3.57	-3.23	-21.31	-25.05
EV/FCF Ratio	-3.84	-3.84	-3.90	92.79	-31.11
Debt / Equity Ratio	0.15	0.15	0.10	-	-
Debt / EBITDA Ratio	-0.23	-0.23	-0.33	-	-
Debt / FCF Ratio	-0.24	-0.24	-0.39	-	-
Quick Ratio	6.64	6.64	14.30	14.98	31.22
Current Ratio	6.93	6.93	14.61	15.33	31.68
Asset Turnover	0.08	0.08	0.12	0.30	0
Interest Coverage	-39.61	-39.61	-27.24	-	-
Return on Equity (ROE)	-74.30%	-74.30%	-32.40%	-7.70%	-33.50%
Return on Assets (ROA)	-58.20%	-58.20%	-27.60%	-7.20%	-23.30%
Return on Capital (ROIC)	-63.12%	-63.12%	-29.53%	-7.29%	-16.27%
Earnings Yield	-11.38%	-20.27%	-15.88%	-2.97%	-3.19%
FCF Yield	-10.30%	-18.35%	-12.67%	0.68%	-2.57%
Buyback Yield / Dilution	-19.35%	-19.35%	-19.78%	-231.12%	-162.72%
Total Shareholder Return	-19.35%	-19.35%	-19.78%	-231.12%	-162.72%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).